Matt Marshall

Helomics

Helomics® is an integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace. Helomics offers scientific and non-scientific product enhancement services and advanced clinical laboratory diagnostic tests to provide a customized solution to our client's specific product development needs. Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains a state-of-the-art research laboratory and a CLIA-certified clinical laboratory. Our novel molecular and cellular markers and bioinformatics services are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual's cancer. Helomics ongoing array of multiple products and technologies provide unique clinical value through a Comprehensive Tumor Profile, which includes: ChemoFx®, BioSpeciFx®, and GeneFx Colon®. This approach to precision medicine combines tumor of origin information, genomic expression and molecular information specific and clinically relevant to a patient's cancer, answering a broad range of clinical questions that physicians encounter every day while managing their patient's care throughout the Continuum of Cancer. Our philosophy: Patients first, therapies second. Personalized healthcare should be comprehensive, precise, predictive, but most importantly, personal. At Helomics, we believe that each patient is unique, and their cancer treatment should be too. Our in-depth approach to characterizing patients'​ live and archived cancer cells allows us to create personal tumor profiles that help physicians to individualize treatment options for their patients.